Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cytarabine/daunorubicin - Jazz Pharmaceuticals

Drug Profile

Cytarabine/daunorubicin - Jazz Pharmaceuticals

Alternative Names: CPX-351; Cytarabine/daunorubicin liposomal; Cytarabine:daunorubicin - Jazz Pharmaceuticals; Cytarabine:daunorubicin liposome injection - Jazz Pharmaceuticals; Daunorubicin/cytarabine; JZP-351; Liposomal AraC-Daunorubicin CPX-351; NS 87; VYXEOS; Vyxeos; Vyxeos Liposomal

Latest Information Update: 03 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Celator Pharmaceuticals
  • Developer Cardiff University; Celator Pharmaceuticals; Children's Oncology Group; Cincinnati Childrens Hospital Medical Center; Fred Hutchinson Cancer Research Center; Jazz Pharmaceuticals plc; National Cancer Institute (USA); Nippon Shinyaku; Pfizer; Stanford University; The Leukemia & Lymphoma Society; University of California at Irvine; University of Washington; Weill Cornell Medical College
  • Class Anthracyclines; Antineoplastics; Arabinonucleosides; Cytostatic antibiotics; Daunorubicins; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action Antimetabolites; DNA intercalators; DNA synthesis inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity No

Highest Development Phases

  • Marketed Acute myeloid leukaemia
  • Phase III Myelodysplastic syndromes
  • Phase II Precursor cell lymphoblastic leukaemia-lymphoma
  • No development reported Haematological malignancies; Lymphoma

Most Recent Events

  • 26 Mar 2024 Registered for Acute myeloid leukaemia in Japan (IV)
  • 14 Sep 2023 Jazz Pharmaceuticals completes a phase II trial in Precursor cell lymphoblastic leukaemia lymphoma in USA (IV, Injection) (NCT03575325)
  • 12 Sep 2023 Jazz Pharmaceuticals completes the V-FAST phase I trial in Acute myeloid leukaemia (First-line therapy, Combination therapy) in USA (IV) (NCT04075747)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top